Cargando…

SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Mei, Jie, Fu, Ziyi, Cai, Yun, Song, Chenghu, Zhou, Jiaofeng, Zhu, Yichao, Mao, Wenjun, Xu, Junying, Yin, Yongmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632109/ https://www.ncbi.nlm.nih.gov/pubmed/37953953 http://dx.doi.org/10.1016/j.isci.2023.108302

Ejemplares similares

SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers
por: Mei, Jie, et al.
Publicado: (2023)

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC
por: Mei, Jie, et al.
Publicado: (2022)

GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC
por: Fan, Honghong, et al.
Publicado: (2023)

GPRC5D as a promising therapeutic target in EGFR-wild and immuno-cold non-small cell lung cancer
por: Mei, Jie, et al.
Publicado: (2023)

Tex19 and Sectm1 concordant molecular phylogenies support co-evolution of both eutherian-specific genes
por: Bianchetti, Laurent, et al.
Publicado: (2015)

Protocol to identify novel immunotherapy biomarkers based on transcriptomic data in human cancers
por: Mei, Jie, et al.
Publicado: (2023)

SECTM1 Produced by Tumor Cells Attracts Human Monocytes Via CD7-mediated Activation of the PI3K Pathway
por: Wang, Tao, et al.
Publicado: (2013)

SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies
por: Wei, Wenwen, et al.
Publicado: (2023)

Pan‐cancer analysis revealing DAAM1 as a novel predictive biomarker for PD‐1/PD‐L1 blockade in clear cell renal cell carcinoma
por: Mei, Jie, et al.
Publicado: (2022)

Angiotensin-converting enzyme 2 identifies immuno-hot tumors suggesting angiotensin-(1–7) as a sensitizer for chemotherapy and immunotherapy in breast cancer
por: Mei, Jie, et al.
Publicado: (2022)

Correction: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
Publicado: (2022)

Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors
por: Cai, Yun, et al.
Publicado: (2021)

Correction to: Upregulation of selected HERVW loci in multiple sclerosis
por: Macías-Redondo, Sofía, et al.
Publicado: (2021)

Correction: Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma
por: Lai, Jinzhi, et al.
Publicado: (2022)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Correction: Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
Publicado: (2021)

Correction to: A proteome-wide immuno-mass spectrometric identification of serum autoantibodies
por: Music, Milena, et al.
Publicado: (2019)

Correction to: Aspinall S, et al. Human Vaccines and Immunotherapeutics Volume 8, Issue 8; pp.1109–18
por: Aspinall, Sanet, et al.
Publicado: (2013)

Author Correction: The immuno-oncological challenge of COVID-19
por: Derosa, Lisa, et al.
Publicado: (2022)

Correction: Observations of Immuno-Gold Conjugates on Influenza Viruses Using Waveguide-Mode Sensors
por: Gopinath, Subash C. B., et al.
Publicado: (2013)

Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
por: Buqué, Aitziber, et al.
Publicado: (2020)

Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
por: Meyers, Daniel E., et al.
Publicado: (2017)

The Long Road of Immunotherapeutics against Multiple Sclerosis †
por: Apostolopoulos, Vasso, et al.
Publicado: (2020)

Correction: GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
Publicado: (2021)

Correction: Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1
Publicado: (2023)

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023)

NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma
por: Ning, Yu-Mei, et al.
Publicado: (2022)

Correction: Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study
por: McKay, James, et al.
Publicado: (2017)

FMNL3 is Overexpressed in Tumor Tissues and Predicts an Immuno-Hot Phenotype in Pancreatic Cancer
por: Zhang, Qinglin, et al.
Publicado: (2022)

Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors
por: Pires, Eusebio S., et al.
Publicado: (2017)

Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo
por: Lu, Xiangdong, et al.
Publicado: (2016)

Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
por: Swan, Dawn, et al.
Publicado: (2019)

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
Publicado: (2023)

Correction: Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer
por: Shao, Fuqiang, et al.
Publicado: (2023)

Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma
por: Feng, Wei, et al.
Publicado: (2023)

Immunotherapeutic Potential of Extracellular Vesicles
por: Zhang, Bin, et al.
Publicado: (2014)

Author Correction: Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction
por: Al‑Darraji, Ahmed, et al.
Publicado: (2021)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Correction to: Mechanisms of multiple neurotransmitters in the effects of Lycopene on brain injury induced by Hyperlipidemia
por: Yang, Weichun, et al.
Publicado: (2018)

Author Correction: Hot carrier cooling mechanisms in halide perovskites
por: Fu, Jianhui, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mm6cvi9n0rbn13ebs1bdi3m985